Sberbank and JSC Pharmasyntez, one of the leaders in the pharmaceutical industry in Russia entered into the cooperation agreement. On October 14, the document was signed by Anatoly Popov, Deputy Chairman of the Executive Board, Sberbank and Vikram Punia, President of JSC Pharmasyntez.
The parties agreed to unite their strength towards the development of the pharmaceutical industry in the Russian Federation in compliance with Pharma-2030 Development Strategy. The agreement provides for interaction in many areas, including joint investments, debt and equity financing, long-term financing of the JSC Pharmasyntez’s projects, digitalization and optimization of production, as well as the introduction of new technologies.
Anatoly Popov, Deputy Chairman of the Executive Board, Sberbank: “We have been cooperating with JSC Pharmasyntez for many years on a wide range of issues. It is our loyal client and reliable partner with a high innovative capacity. In preceding times, we approved to the company a credit limit of 15 billion rubles. The today’s agreement and expansion of interaction will ensure the increased export of pharmaceuticals and innovation in manufacturing processes, as well as help to accelerate the development of this strategically important industry, upon the continuous work of which people’s lives are dependent”.
Vikram Punia, President of JSC Pharmasyntez: “Sberbank has been our strategic and financial partner for many years. The united strength of JSC Pharmasyntez and Sberbank will ensure production modernization with implementation of the advanced technologies and creation of a sustainable innovative basis for JSC Pharmasyntez. The attracted investments, as well as implementation of the new technologies will be focused on clinical studies of the candidate drugs in Russia and abroad and investments development, and high growth rates of the Pharmasyntez Group of Companies for the period until 2025.
Aleksandr Abramkin, Chairman of Baikalsky Sperbank: “An online execution of the agreement, a milestone event, took place in Moscow today. This is a very important resonance for the Irkutsk region, since JSC Pharmasyntez is a very significant link in a chain of economic potential of the Angara Region, where one of the major factories of the company is located. And certainly a new stage of cooperation between Sberbank and the pharmaceutical company will give an additional impetus to the development and improvement of the company. We are glad that our cooperation can arrive at a new level”.
PAO Sberbank is one the largest Russian banks and one of the leading global financial institutions, which accounts for about one third of assets of all Russian banking sector. Sberbank is a key creditor for the national economy and holds one of the largest shares in the deposit market. The main shareholder of PAO Sberbank is the Russian Federation represented by the ministry of Finance of the Russian Federation, possessing 50% of the authorized capital of PAO Sberbank and 1 voting share. The remaining 50% (except for 1 voting share of the authorized capital of the bank) are possessed by the Russian and for-eign investors. The clients from 18 countries of the world use the services of Sberbank. The bank has an extensive branch network in Russia: about 14 thousand service points. The broad banking network comprises subsidiary banks, branches and representative offices in Great Britain, USA, CIS countries, Central and East Europe, India, China, and other countries. General License of Bank of Russia No 1481 dated 11.08.2015. Official bank web-sites: www.sberbank.com (Sberbank Group web-site), www.sberbank.ru.
On September 24, 2020 Sberbank conducted rebranding and offers to its private and corporative clients financial and non-financial services of the bank and Sberbank Group of companies. Today the Sber Ecosystem is a multiple service for life, daily assistance in solving urgent problems of private clients and business. The Sber Ecosystem website is www.sber.ru.